Latest Breaking News On - Prnewswire halozyme therapeutics inc - Page 3 : vimarsana.com

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSamantha gasparHelen torleyEli lillyBristol myers squibbEuropean commissionPrnewswire halozyme therapeutics incIdorsia pharmaceuticalsExchange commissionTeva pharmaceuticalsDrug administrationCorporate communicationsAcumen pharmaceuticalsEuropean medicines agencyHalozyme therapeutics inc

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSamantha gasparHelen torleyEli lillyBristol myers squibbJapan ministry of healthTeva pharmaceuticalsPrnewswire halozyme therapeutics incIdorsia pharmaceuticalsCorporate communicationsHalozyme therapeutics incAcumen pharmaceuticalsExchange commissionHorizon therapeuticsViiv healthcare

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU s First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of.

San diegoUnited statesHelen torleySamantha gasparEli lillyCorporate communicationsAcumen pharmaceuticalsExchange commissionPrnewswire halozyme therapeutics incEuropean unionRoche groupHalozyme therapeutics incIdorsia pharmaceuticalsEuropean commissionTeva pharmaceuticalsBristol myers squibb

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval.

San diegoUnited statesSamantha gasparEli lillyHelen torleyPrnewswire halozyme therapeutics incBristol myers squibbExchange commissionCorporate communicationsAcumen pharmaceuticalsTeva pharmaceuticalsHalozyme therapeutics incDrug administrationIdorsia pharmaceuticalsHorizon therapeuticsViiv healthcare

Halozyme To Present At Upcoming Investor Conferences

Halozyme To Present At Upcoming Investor Conferences
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoNew yorkEli lillyPiper sandlerNicole labrosseHelen torleyHalozyme therapeutics incTeva pharmaceuticalsPrnewswire halozyme therapeutics incIdorsia pharmaceuticalsAcumen pharmaceuticalsBristol myers squibbCorporate communicationsAnnual healthcareChief financial